Attana completes share issue

Attana has completed its new share issue and will receive SEK 10.5 million before costs. More than SEK 6.1 million was subscribed for by approximately 500 individuals and the guarantee consortium subscribed an additional SEK 3.9 million. In addition, liabilities of SEK 0.5 million have been settled. The company has applied for listing of the shares on NGM Nordic MTF.

The share issue was conducted in accordance with the decision of an Extraordinary General Meeting held on October 10, 2017. The subscription price was SEK 0.60/share and the subscription period ran from the 9th until the 30th of November 2017.

A total of 17,500,000 shares will be issued to approximately 500 subscribers and settlement notes will be sent to the subscribers this week.

"We are pleased to welcome the new shareholders to Attana and look forward to creating increased growth and profitability in the company. There has been a lot of interest from investors which I have met during the subscription period and together with our approximately 3,700 existing shareholders we are now poised to create a company that makes a difference in drug development," says Teodor Aastrup, CEO Attana.

Through the issue, 17,500,000 new shares are issued and the share capital increases by SEK 105,000. Following the issue, the share capital of the company will amount to SEK 730,581 divided into 121,763,500 shares.

For more information, please contact:

Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com 
tel: + 46 (0)8 41020000

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences.  To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact  sales@attana.com

About Us

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact sales@attana.com.

Subscribe

Documents & Links